The European Union’s health regulator has lifted the temporary restriction on the use of French drugmaker Valneva’s chikungunya vaccine, Ixchiq, in adults aged 65 and above, following a safety review.

Just as new outbreaks of chikungunya threaten to become another epidemic, Bavarian Nordic, maker of a vaccine against the ...

The Centers for Disease Control and Prevention (CDC) is warning about the deadly mosquito-borne chikungunya virus, which is ...

Chikungunya virus disease, a debilitating mosquito-borne (Aedes spp) illness caused by an alphavirus, chikungunya virus, is usually endemic in regions with tropical climates.1 Since the beginning of ...

At its July meeting, the European Medicines Agency’s pharmacovigilance committee (PRAC) completed its review of French specialty vaccine maker Valneva Ixchiq (chikungunya virus vaccine, a live ...

Additionally, EMA noted that while most serious side effects occurred in older people, IXCHIQ ® is effective at triggering the production of antibodies against the chikungunya virus which may be ...

July, 11 2025 - Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the European Medicines Agency (EMA) will lift the temporary ...

Saint Herblain (France), July, 11 2025 - Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the European Medicines Agency (EMA) will lift the temporary ...

WASHINGTON, DC (IANS) – The US Food and Drug Administration (FDA) has approved the world’s first chikungunya vaccine, an affliction that is common in India. The vaccine Ixchiq, developed by ...

Saint Herblain (France), July, 11 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the European Medicines Agency (EMA) will lift the temporary ...

IXCHIQ ® was authorised in the European Union in June 2024 2 and, in March 2025, the European Commission granted a label extension in adolescents 12 years of age and older 3. About Chikungunya ...